According to a recent Reuters article, drug giant Eli Lilly and Co. has requested that the FDA de-authorize its COVID-19 antibody, bamlanivimab. The unique request isn’t linked to safety issues, but in response to new variants of the virus that could be resistant to bamlanivimab when used alone. The government agreed, and stopped distribution of the therapy last month. Facilities that still have supply are being shipped etesevimab to pair with it for a combination treatment that’s more effective.
Eli Lilly Asks FDA to Cancel COVID-19 Antibody Authorization
The pharmaceutical giant will use the antibody as part of a combination treatment for greater efficacy.
Apr 23, 2021
Researched List: Blister Machines for Life Sciences
Need a blister machine for life sciences packaging? Our curated list features companies serving pharmaceutical, medical device, nutraceutical, and cosmetic industries. Download to access company names, locations, machine specifications, descriptions, and more.
Download Now
Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
